Biomarkers in Tissue Samples From Older Women With Breast Cancer

July 1, 2016 updated by: Alliance for Clinical Trials in Oncology

PIK3CA Mutation Status as a Biomarker in Elderly Women With Breast Cancer

This research trial studies phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutation analysis in tissue samples from older patients with stage I breast cancer. Studying samples of tissue from patients with stage I breast cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.

Study Overview

Status

Terminated

Conditions

Breast Cancer

Intervention / Treatment

Other: laboratory biomarker analysis

Detailed Description

PRIMARY OBJECTIVES:

To assess the relapse free-survival difference between patients with PIK3CA mutated and wild-type (WT) tumors and therefore validate PIK3CA mutation status as an important biomarker in women 70 years or older diagnosed with breast cancer.

OUTLINE:

Previously collected tissue samples are analyzed via mutation analysis of PIK3CA.

Study Type

Observational

Enrollment (Actual)

505

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

70 years and older (Older Adult)

Accepts Healthy Volunteers

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Patients with breast cancer enrolled on Cancer and Leukemia Group B 9343

Description

Participants with stage I breast cancer (T1N0M0) and estrogen-receptor status positive or unknown
Patients underwent lumpectomy with negative margins and were clinically node-negative

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Observational Models: Case-Only
Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Breast cancer-free interval for patients with PIK3CA-mutated tumors Time Frame: baseline	baseline
Tumor size Time Frame: baseline	baseline
Estrogen receptor status Time Frame: baseline	baseline
Lymph node status Time Frame: baseline	baseline
Treatment group associated with PIK3CA expression Time Frame: baseline	baseline

Secondary Outcome Measures

Outcome Measure	Time Frame
Overall survival associated with PIK3CA Time Frame: baseline	baseline
Breast cancer specific survival associated with PIK3CA expression Time Frame: baseline	baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Alliance for Clinical Trials in Oncology

Collaborators

National Cancer Institute (NCI)

Investigators

Study Chair: Mary Ellen Moynahan, MD, Memorial Sloan Kettering Cancer Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2011

Primary Completion (Actual)

January 1, 2014

Study Completion (Actual)

January 1, 2014

Study Registration Dates

First Submitted

April 30, 2011

First Submitted That Met QC Criteria